YYÜ GCRIS Basic veritabanının içerik oluşturulması ve kurulumu Research Ecosystems (https://www.researchecosystems.com) tarafından devam etmektedir. Bu süreçte gördüğünüz verilerde eksikler olabilir.
 

Silymarin Ameliorates Cisplatin-Induced Nephrotoxicity by Downregulating Tnf-Α and Nf-Kb and by Upregulating Il-10

dc.authorscopusid 57193389674
dc.contributor.author Altindaǧ, F.
dc.date.accessioned 2025-05-10T16:54:11Z
dc.date.available 2025-05-10T16:54:11Z
dc.date.issued 2022
dc.department T.C. Van Yüzüncü Yıl Üniversitesi en_US
dc.department-temp Altindaǧ F., Department of Histology and Embryology, Faculty of Medicine, Van Yuzuncu Yil University, Van, Turkey en_US
dc.description.abstract Cisplatin (CP) is one of the antineoplastic agents used to treat many types of cancers. Besides these effects of CP, it causes various side effects such as nephrotoxicity. Inflammation is considered to be one of the main pathogeneses of CP-induced nephrotoxicity. Silymarin (SIL) is a flavonoid with beneficial pharmacological properties such as antioxidant and anti-inflammatory. The current study aimed to investigate the beneficial effects of Silymarin against CP-induced nephrotoxicity. Albino Wistar male rats were randomly divided into four groups (n=7): Control group was administered saline (0.5 ml) for 10 days intraperitoneally (IP), CP group was received CP (a single dose of 8 mg/kg, IP), CP+ SIL group was administered saline (0.5 ml) for 10 days and was received CP (a single dose of 8 mg/kg). To measure the inflammatory response, TNF- α, NF-kB and IL-10 expressions were performed. As a result, TNF-α and NF-kB expressions significantly increased while IL-10 expression decreased in the kidney of the CP group compared to the control group. However, SIL treatment significantly decreased TNF-α and NF-kB expressions and increased IL-10 expression in kidney CP-treated rats. These findings reveal that SIL may ameliorates the CP-induced nephrotoxicity in rats by inducing downregulation of TNF-α and NF-kB expressions and upregulation of IL-10 expression. © 2022 Ondokuz Mayis Universitesi. All rights reserved. en_US
dc.identifier.doi 10.52142/omujecm.39.1.42
dc.identifier.endpage 220 en_US
dc.identifier.issn 1309-4483
dc.identifier.issue 1 en_US
dc.identifier.scopus 2-s2.0-85131969414
dc.identifier.scopusquality Q4
dc.identifier.startpage 216 en_US
dc.identifier.uri https://doi.org/10.52142/omujecm.39.1.42
dc.identifier.uri https://hdl.handle.net/20.500.14720/3026
dc.identifier.volume 39 en_US
dc.identifier.wosquality N/A
dc.institutionauthor Altindaǧ, F.
dc.language.iso en en_US
dc.publisher Ondokuz Mayis Universitesi en_US
dc.relation.ispartof Journal of Experimental and Clinical Medicine (Turkey) en_US
dc.relation.publicationcategory Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı en_US
dc.rights info:eu-repo/semantics/openAccess en_US
dc.subject Cisplatin en_US
dc.subject Il-10 en_US
dc.subject Nephrotoxicity en_US
dc.subject Nf-Kb en_US
dc.subject Silymarin en_US
dc.subject Tnf-Α en_US
dc.title Silymarin Ameliorates Cisplatin-Induced Nephrotoxicity by Downregulating Tnf-Α and Nf-Kb and by Upregulating Il-10 en_US
dc.type Article en_US

Files